Public
- ACI Events
- ACI Locations
- Active Communications International Blog/Forum
- Active Communications International News
- European Prefilled Syringes Summit
If this is your company, CONTACT US to activate Packbase™ software to build your portal.
Widya started as Public Affairs and Communications Director of Pfizer in 2011. Prior to that, Widya was the Legal Director for Pfizer Indonesia and had given Legal services since 2002 where she joined Pfizer as Legal Manager. During her tenure in Legal, she had a one year experience of managing legal affairs of Pfizer Singapore (2010 – 2011).
In her current role, one of her responsibility is to ensure Pfizer’s good reputation in the eye of its stakeholders be maintained. In addition to her roles in Pfizer, she has been asked by the external stakeholders to also take part and lead the Indonesian Anti-Counterfeiting Society or known in Indonesia abbreviation as MIAP. She holds the chairmanship of this association since 2008 and since then has increased the awareness from the stakeholders to jointly combat counterfeit. Various partnerships with stakeholders have been built up under her initiative in order to carry out Pfizer's objectives such as in the area of Intellectual Property Rights and related health policy.
Widya’s legal degree was obtained from Faculty of Law of the University of Indonesia and her master degree in Strategic Management from Prasetiya Mulya Business School, Jakarta. Currently she has been admitted in a Doctoral Program in Law at University of Pelita Harapan, Indonesia. She has also published an inspirational book of her own in 2015.
Early Confirmed Speakers:
- Widyaretna Buenastuti, Public Affairs & Communications Director, Pfizer Indonesia
- May Ng, Regulatory And Quality Consultant,Founder, ARQon Pte Ltd
- Shibu Baburaj, Head, Regulatory Affairs, Sanofi-Aventis
- Dimas Adityo, Compliance Director/Head of Ethics & Business Integrity, Sanofi Indonesia
- Regulatroy submissions implementation in eCTD format
- The ASEAN Labelling Harmonisation Effort
- Registration and approval timeline – combination products and exemptions
- What’s new with clinical regulatory requirements in Asia Pacific?
- Global trends vs. specific region’s updates for pharmacovigilance
- Regulatory affairs support in providing advices to commercial team for inspection
- Global Guidelines for the Development of Biologics
Location
Telephone: +65 203 141 0606 Country: Singapore